MGNX Earnings Date: Nov 11, 2026 (Estimated) — MacroGenics, Inc.
NASDAQ
Updated
When is MGNX's next earnings date?
MacroGenics, Inc. (MGNX) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.10 on revenue of $39.2M.
How did MGNX do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), MacroGenics, Inc. posted EPS of -$0.27 versus the -$0.08 estimate, a miss of 292.9%. Revenue was $32.8M against a $59.1M estimate. The stock's 1-day post-earnings move was +3.4%.
How much does MGNX stock move after earnings?
MGNX beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.0% (up or down) in the day after earnings.
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.08 | -0.27 | -292.86% | $32.8M | ❌ Miss | +3.43% | -0.61% | +2.94% |
| 2026-05-13 | Q1 2026 | -0.55 | -0.58 | -5.45% | $20.8M | ❌ Miss | +20.58% | +29.28% | +14.78% |
| 2026-03-09 | Q4 2025 | -0.18 | -0.22 | -22.22% | $41.2M | ❌ Miss | +45.34% | +31.36% | +46.19% |
| 2025-11-12 | Q3 2025 | -0.39 | 0.27 | +169.23% | $72.8M | ✅ Beat | +8.84% | -3.40% | -4.76% |
| 2025-08-14 | Q2 2025 | -0.01 | -0.57 | -5600.00% | $22.2M | ❌ Miss | -2.47% | -11.11% | -3.70% |
| 2025-03-20 | Q4 2024 | -0.59 | -0.25 | +57.63% | $19.4M | ✅ Beat | -5.00% | -29.52% | -33.81% |
| 2024-11-05 | Q3 2024 | 0.21 | 0.90 | +328.57% | $110.7M | ✅ Beat | +11.14% | +8.75% | -10.08% |
| 2024-08-06 | Q2 2024 | -0.59 | -0.89 | -50.85% | $10.8M | ❌ Miss | -7.14% | -3.02% | -7.14% |
Showing last 8 quarters.